71 Participants Needed

Povorcitinib for Healthy Subjects

IC
IC
Overseen ByIncyte Corporation Call Center (US)
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

What is the purpose of this trial?

The purpose of this study is to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics and the Effect of Probenecid on Povorcitinib Pharmacokinetics When Administered Orally to Healthy Adult Participants.

Research Team

IM

Incyte Medical Monitor

Principal Investigator

Incyte Corporation

Eligibility Criteria

This clinical trial is for healthy adults. Specific eligibility criteria are not provided, but typically participants should have no significant health issues and be on no other medications that could affect the study results.

Inclusion Criteria

No clinically significant findings on screening evaluations (eg, clinical, laboratory, and ECG evaluations)
Willingness to avoid pregnancy or fathering children based on specific criteria for male and female participants
I can swallow and keep down pills.
See 2 more

Exclusion Criteria

I cannot have blood drawn from my veins.
I do not have any active infections.
History or presence of an abnormal ECG
See 27 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks

Treatment

Participants receive oral administration of povorcitinib with digoxin, rosuvastatin, metformin, or probenecid as per cohort assignment

3 weeks
Multiple visits for drug administration and monitoring

Follow-up

Participants are monitored for safety and effectiveness after treatment

1-2 weeks

Treatment Details

Interventions

  • Povorcitinib
Trial Overview The study is testing how Povorcitinib affects the body's handling of three drugs: Digoxin (used for heart problems), Rosuvastatin (for cholesterol), and Metformin (for diabetes) when taken by mouth in healthy people.
Participant Groups
4Treatment groups
Experimental Treatment
Group I: Cohort 4: DoseExperimental Treatment2 Interventions
Probenecid and povorcitinib will be administered at protocol defined doses.
Group II: Cohort 3: DoseExperimental Treatment2 Interventions
Metformin and povorcitinib will be administered at protocol defined doses.
Group III: Cohort 2: DoseExperimental Treatment2 Interventions
Rosuvastatin and povorcitinib will be administered at protocol defined doses.
Group IV: Cohort 1: DoseExperimental Treatment2 Interventions
Digoxin and povorcitinib will be administered at protocol defined doses.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Incyte Corporation

Lead Sponsor

Trials
408
Recruited
66,800+
Steven Stein profile image

Steven Stein

Incyte Corporation

Chief Medical Officer since 2015

MD from University of Witwatersrand

Hervé Hoppenot profile image

Hervé Hoppenot

Incyte Corporation

Chief Executive Officer since 2014

MBA from ESSEC Business School

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security